The nChroma Bio, a leading genetic medicines company developing in vivo delivery of unique cargoes to address the limitations of the previous therapies, has received approval for its three abstracts, as well as the poster of distinction that will be officially confirmed at the upcoming AASLD liver meeting held at Washington, DC, on November 6 to 11, 2025.
Phd, Chief Development Officer of nChroma, Jenny Marlowe, said, “At AASLD, we will be highlighting the thoroughness of standards implicated in the design of our well-known chronic hepatitis B program, CRMA-1001. The program mirrors nChroma Bio’s dedication to serve an epigenetic silencing solution with the proven capability for superior efficacy at lower doses.”
The title of the poster is ‘preclinical pharmacology and safety of CRMA-1001, a novel epigenetic editor for chronic hepatitis B that demonstrates HBV surface antigen loss in animal models via precise HBV DNA methylation.’ The presenter of the poster is Sarah Voytek, phd, presenting under the hepatitis B session, holding a publication number ‘1118’. It will be held on 7th November 2025 between 8:00 am – 5:00 pm.
The additional poster presentation’s title is ‘epigenetic editors targeting chronic hepatitis B achieve HBV surface antigen loss with a single course of treatment in multiple HBV mouse models.’ The presenter is Glen Acosta, phd, to project under the session of hepatitis B with the publication no. 1262 on 7th November 2025 between 8:00 am – 5:00 pm. The other presentation’s title is ‘establishment of assay limits for differential gene expression and DNA methylation to characterize specificity of epigenetic editing’. The presenter will be Erica Hildebrand, phd, to project under the session heading genomics and precision medicine (publication no. 4304) on 10th November 2025 between 8:00 am – 5:00 pm.
The company has been dedicatedly to accelerating its complementary scientific approaches to match innovative cargo with focuse-accuracy in vivo delivery methods. With this approval and entry through the meeting will empower the company to advance in vivo delivery of unique cargoes. The three abstractions prove to be adaptive for the existing therapies. This is an achievement and a sense of acceptance of nChroma’s initiative to develop and build a strong formation in the improvisation areas of the existing therapies. The company has taken a step ahead with the disease-first approach to engineer customized genetic medicines.
Holding M.Pharm in Pharmaceutical Chemistry, Chandni crafts cutting-edge, research-driven healthcare news for Towards Healthcare, combining scientific depth with innovative storytelling to simplify complex topics for global readers.
